Medinoah is a global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), established in 2008. We specialize in providing comprehensive and flexible solutions across the entire spectrum of small molecule drug discovery, development, and manufacturing.

A key area of our expertise lies in the synthesis, scale-up, and GMP production of protein degraders and molecular glues. Our core services include medicinal chemistry FTE/FFS, catalog compounds, building blocks, route scouting, process optimization, and rapid scale-up in both non-GMP and GMP environments. We are also well-equipped to handle PPQ and PV for RSMs and APIs.

Our analytical and regulatory capabilities include genotoxic impurity assessment and control, analytical method development and validation, stability studies, and filing preparation and review.

At Medinoah, our culture of scientific innovation is driven by state-of-the-art infrastructure, enabling us to deliver integrated solutions tailored to the needs of our partners in drug discovery and development.

Media

---